CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Świdnik,, Poland

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

    This is a prospective, multi center, multinational, non-interventional observational study. All patients will be managed according to the clinical site's normal clinical practice, i.e., the diagnostic and clinical treatment/practice process that a clinician chooses according to their clinical judgement for an SMA patient. Clinical care will not be driven by the protocol. No additional visits or investigations will be performed beyond normal clinical practice. Patients will be followed for 15 years from enrolment or until death, whichever is sooner.

    Phase

    N/A

    Span

    1032 weeks

    Sponsor

    Novartis Pharmaceuticals

    Toon, Ehime

    Recruiting

  • Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

    Phase

    2

    Span

    177 weeks

    Sponsor

    Kowa Research Institute, Inc.

    Toon, Ehime

    Recruiting

  • A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

    Phase

    3

    Span

    242 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

    Phase

    3

    Span

    273 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

    Phase

    3

    Span

    214 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

    Phase

    3

    Span

    1302 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

    Phase

    3

    Span

    222 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

    Phase

    3

    Span

    248 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    All participants undergo an initial induction phase of four cycles, each cycle consisting of pembrolizumab q3w + carboplatin q3w + paclitaxel q3w or nabpaclitaxel weekly. Participants are then randomly assigned to pembrolizumab maintenance vs. pembrolizumab + sac-TMT maintenance.

    Phase

    3

    Span

    349 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Toon, Ehime

    Recruiting

  • Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

    CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.

    Phase

    2

    Span

    128 weeks

    Sponsor

    Mirati Therapeutics Inc.

    Toon, Ehime

    Recruiting

1-10 of 14
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information